Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.82 |
| ▸ | PLK4 | O00444 | 8/20 | 0.82 |
| ▸ | MAP4K4 | O95819 | 8/20 | 0.82 |
| ▸ | MARK3 | P27448 | 8/20 | 0.82 |
| ▸ | AXL | P30530 | 8/20 | 0.82 |
| ▸ | MAP4K2 | Q12851 | 8/20 | 0.82 |
| ▸ | STK3 | Q13188 | 8/20 | 0.82 |
| ▸ | SLK | Q9H2G2 | 8/20 | 0.82 |
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.82 |
| ▸ | MINK1 | Q8N4C8 | 7/20 | 0.82 |
| ▸ | LCK | P06239 | 7/20 | 0.82 |
| ▸ | BLK | P51451 | 7/20 | 0.82 |
| ▸ | LIMK1 | P53667 | 7/20 | 0.82 |
| ▸ | MARK2 | Q7KZI7 | 7/20 | 0.82 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.82 |
| ▸ | AURKA | O14965 | 7/20 | 0.82 |
| ▸ | CDK1 | P06493 | 6/20 | 0.82 |
| ▸ | BRSK1 | Q8TDC3 | 6/20 | 0.82 |
| ▸ | MET | P08581 | 6/20 | 0.82 |
| ▸ | MAP4K5 | Q9Y4K4 | 6/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719687 | 0.90 | MAP4K4 (0.78) | KDRPLK4MAP4K4MARK3AXL | |
| SCHEMBL5472353 | 0.90 | KDR (1.00) | KDRPLK4MAP4K4MARK3AXL | |
| SCHEMBL5475465 | 0.85 | KDR (0.78) | KDRPLK4MAP4K4MARK3AXL | |
| SCHEMBL4720555 | 0.84 | PLK4 (0.89) | KDRPLK4MAP4K4MARK3AXL | |
| SCHEMBL4762855 | 0.83 | KDR (1.00) | KDRPLK4MAP4K4MARK3AXL | |
| SCHEMBL4722704 | 0.82 | PLK4 (0.79) | KDRPLK4MAP4K4MARK3AXL | |
| SCHEMBL5474900 | 0.81 | PLK4 (0.80) | KDRPLK4MAP4K4MARK3AXL | |
| SCHEMBL4719761 | 0.80 | PLK4 (1.00) | KDRPLK4MAP4K4MARK3AXL | |
| SCHEMBL5478260 | 0.80 | PLK4 (1.00) | KDRPLK4MAP4K4MARK3AXL | |
| SCHEMBL5469023 | 0.79 | KDR (0.78) | KDRPLK4MAP4K4MARK3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968979-A2 | 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007067781-A2 | 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135387-A1 | Inhibitors of protein kinases | ABBOTT LABORATORIES | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135387-A1 | Inhibitors of protein kinases | MAP3K20, PACSIN2, MAP4K2 | KDR 2196/4885PLK4 230/4885MAP4K4 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.